{
  "docId": "019de070-dce8-70ee-8639-85282f075771",
  "docSlug": "622e4280fc41e900213786c9a95190a7",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 40,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 26,
  "notes": "The slide uses stacked bar charts to show revenue composition over time (Q1 2018 - Q1 2021).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-dce8-70ee-8639-85282f075771/15",
  "deckHref": "/decks/019de070-dce8-70ee-8639-85282f075771",
  "deckJsonHref": "/decks/019de070-dce8-70ee-8639-85282f075771.json",
  "deckAnchorHref": "/decks/019de070-dce8-70ee-8639-85282f075771#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Farxiga 50% growth",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22674ff4-f6ed-4125-b58a-947301c7d9b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "chart",
      "text": "New CVRM 15% growth",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb87c129-5e0f-40ed-8c89-71583b14c6cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.68,
        "y": 0.3
      },
      "kind": "list",
      "text": "US +16% Strong volume growth including HFrEF indication, but offset by price impact. Europe +36% Solid volume growth boosted by initial launch of HFrEF indication. EMs +85% Benefit from NRDL inclusion in China and also strong growth elsewhere.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7e59fae-8cfe-4082-995f-0cf859102029",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.68,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1. Sodium-glucose co-transporter 2 inhibitor 2. Heart failure with reduced ejection fraction.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b12f187-05a9-4094-8e02-eed59af3594d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "BioPharmaceuticals: New CVRM 15% growth boosted by Farxiga and EMs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cbe7a6d6-46a4-4fe3-9a49-30d75e1de4e3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "16cc6fbe-83db-4b9c-9710-30f2c521a7a8",
      "evidence": "chart/bar-stacked: New CVRM 15% growth and chart/bar-stacked: Farxiga 50% growth",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}